Wnt-Signaling-Mediated Antiosteoporotic Activity of Porcine Placenta Hydrolysates in Ovariectomized Rats

Table 4

Bone turnover marker levels at the end of the 12-week treatment.

	OVX-control	OVX-WPPH	OVX-NPPH	OVX-EST	Sham-control
	(𝑛=10)	(𝑛=10)	(𝑛=10)	(𝑛=10)	(𝑛=10)
Serum osteocalcin (ng/mL)	8.8 ± 1.1^a	7.9 ± 1.0^ab	7.2 ± 0.9^b	6.3 ± 0.8^c*	6.1 ± 0.6^†
Serum ALP; (IU/L)	197 ± 27.8^a	174 ± 28.4^ab	153 ± 26.7^b	135 ± 18.9^c*	142 ± 17.5^†
Serum BSALP; (IU/L)	19.3 ± 2.6^a	18.0 ± 2.3^ab	16.8 ± 2.0^b	15.7 ± 1.9^b*	15.5 ± 2.1^†
Urinary DPD; (nmol/mmol creatinine)	38.7 ± 4.2^a	33.7 ± 4.1^ab	29.2 ± 3.8^b	23.4 ± 3.1^c*	24.7 ± 3.5^††

ALP: alkaline phosphatase; BSALP: bone-specific alkaline phosphatase; DPD: deoxypyridinoline. Values are mean ± SD. *Significantly different among the different treatments in OVX rats at P < 0.05. ^a,b,cValues with different superscripts were significantly different among the OVX groups by Tukey’s test at P < 0.05. ^†Significantly different between OVX-control and Sham-control at P < 0.05, ^††P < 0.01.